American International Group Inc. Purchases New Holdings in AVITA Medical, Inc. (NASDAQ:RCEL)

American International Group Inc. purchased a new stake in shares of AVITA Medical, Inc. (NASDAQ:RCEL) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,100 shares of the company’s stock, valued at approximately $206,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RCEL. Millennium Management LLC bought a new stake in shares of AVITA Medical in the 2nd quarter valued at approximately $1,269,000. Renaissance Technologies LLC bought a new stake in shares of AVITA Medical in the 1st quarter valued at approximately $1,826,000. Jane Street Group LLC bought a new stake in shares of AVITA Medical in the 1st quarter valued at approximately $1,968,000. Susquehanna International Group LLP grew its stake in shares of AVITA Medical by 88.3% in the 1st quarter. Susquehanna International Group LLP now owns 230,077 shares of the company’s stock valued at $3,214,000 after purchasing an additional 107,868 shares during the period. Finally, Globeflex Capital L P grew its stake in shares of AVITA Medical by 183.0% in the 1st quarter. Globeflex Capital L P now owns 118,862 shares of the company’s stock valued at $1,661,000 after purchasing an additional 76,856 shares during the period. 29.88% of the stock is currently owned by institutional investors.

AVITA Medical Price Performance

NASDAQ RCEL opened at $12.54 on Tuesday. The stock’s 50 day simple moving average is $11.94 and its 200 day simple moving average is $14.65. AVITA Medical, Inc. has a one year low of $6.29 and a one year high of $21.70. The firm has a market cap of $320.41 million, a PE ratio of -9.43 and a beta of 1.54.

Analyst Upgrades and Downgrades

RCEL has been the topic of several analyst reports. Piper Sandler lowered their price objective on AVITA Medical from $23.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, November 10th. Bank of America increased their price target on AVITA Medical from $18.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $26.00 price target on shares of AVITA Medical in a research report on Thursday, October 19th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $27.60.

About AVITA Medical

AVITA Medical, Inc operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.